Loading
A phase 3 trial of Adebrelimab, Cisplatin, Carboplatin in cervical cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer is a phase 3 interventional study registered as NCT07168200 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 720 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-04. Interventions recorded: SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection, Paclitaxel Injection, SHR-1316 Placebo Injection. Conditions listed: Advanced Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.